| Toggle Summary
|
Galectin Therapeutics to Announce New Data on the Treatment of Fatty Liver Disease and Fibrosis
-- Abstract Accepted for Presentation at the European Association for Study of the Liver Special Conference on Liver Transplantation --
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Elects Dr. Marc Rubin to its Board of Directors
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Board Member John Mauldin Plans to Purchase Stock Under 10b5-1 Plan; Company Featured in his e-newsletter "Thoughts from the Frontline"
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Posts New Corporate Presentation Video to its Website
Highlights Leadership Position Developing Galectin-Inhibiting Therapeutics to Treat Fibrosis & Cancer
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics to Present Corporate Update at the Rodman & Renshaw HealthcareConference
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Reports Financial Results for Second Quarter 2011
|
View HTML
|
| Toggle Summary
|
10X Fund Issues Statement Regarding Investment in Galectin Therapeutics
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Announces Research Collaboration with Dr. Jose Jalife of the University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease
|
View HTML
|
| Toggle Summary
|
ADDING and REPLACING Galectin Therapeutics Announces New Stock Trading Symbol "GALT"
|
View HTML
|
| Toggle Summary
|
Galectin Therapeutics Expands European Patent Coverage
Patent Covers Use of GM-CT-01 with Chemotherapy to Increase Effectiveness and Reduce Side Effects of Cancer Treatments
|
View HTML
|
